GlobeNewsWire
17 Mar 2026, 14:54 UTC · 27w ago
Verdict
Headline takes no side. We score ALDX −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
The FDA declined to approve Aldeyra Therapeutics' lead investigational drug, reproxalap, for the treatment of dry eye disease due to insufficient evidence of efficacy.
So whatThe failure of a lead drug candidate is a catastrophic event for a biotechnology company's valuation and pipeline.
More negative than 99% of claims this week
Aldeyra Therapeutics' stock price declined by more than 70% in early morning trading on March 17, 2026.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 99% of claims this week
The law firm Johnson Fistel, PLLP is investigating Aldeyra Therapeutics for potential violations of federal securities laws regarding investor losses.
More negative than 87% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The FDA declined to approve its lead drug, leading to a stock decline of over 70% and a securities fraud investigation.
More negative than 76% of ticker scores this week
The company is under investigation by a law firm on behalf of investors who suffered losses.
More negative than 76% of ticker scores this week
The company is under investigation for potential securities law violations following investor losses.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
42m ago
−68.3%
Price agrees with the score
$1.34 vs $4.23 close before publication (Mar 16) · not market-adjusted
ALDX chart →
